OIV INFEKSIYALI SHAXSLARDA YONDOSH PATOLOGIYALAR CHASTOTASI
Ключевые слова:
OIV infeksiyasi, yondosh patologiyalar, opportunistik kasalliklar, xayrixohlik, komplayensАннотация
Dolzarbligi. Antiretrovirus terapiyaning rivojlanishi OIV bilan yashayotgan shaxslar umrini uzaytirdi, biroq ularning qarishi fonida yondosh patologiyalar va davolashga xayrixohlik (komplayens) masalasi yangi klinik muammolarni yuzaga keltirmoqda. Maqsad. Respublika OITSga qarshi kurashish markazida dispanser nazoratida turgan OIV infeksiyali shaxslar o‘rtasida yondosh kasalliklarning uchrash chastotasini aniqlash va ularning retrovirusga qarshi terapiyaga (RQT) bo‘lgan xayrixohlik darajasini baholash. Material va usullar. Tadqiqotga 2025–2026 yillarda OIV infeksiyasining 3-4 klinik bosqichida bo‘lgan va kamida 6 oydan beri RQT qabul qilayotgan 127 nafar erkak jinsiga mansub bemorlar jalb etildi. Klinik, anketa-so‘rovnoma va statistik (SPSS 26.0) usullardan foydalanildi. Natijalar. Bemorlarning 91,3 foizi 40 yoshdan oshgan shaxslardir. Tarqalgan limfodenopatiya 100% holatda, Gerpes Zoster — 26,0%, sitomegalovirusli infeksiya — 24,4%, kandidozlar — 16,5%, invaziv aspergellez — 14,2%, tuberkulyoz va gepatit V — 8,7% dan holatda aniqlandi. Bemorlarning atigi 26,0 foizida RQTga nisbatan yuqori xayrixohlik (>95%) kuzatildi, 70,9 foizida esa o‘rtacha xayrixohlik (80-95%) qayd etildi. Xulosa. 3-4 klinik bosqichdagi OIV infeksiyali erkaklarda populyatsiyaning qarishi va og‘ir virusli hamda zamburug‘li yondosh patologiyalarning yuqori chastotasi kuzatilmoqda. RQTga xayrixohlikning asosan o‘rtacha darajada ekanligi (70,9%) komorbidlik sharoitida tibbiy nazoratni kuchaytirishni taqozo etadi.
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Ахмедов А. А., Шукуров Б. С. ОИВ инфекцияси бўлган беморларда ҳамроҳ касалликларнинг учраш хусусиятлари. Тиббиётда янги кун (New Day in Medicine). 2023;4(52):112-117.
2. Иванов И. И., Петров П. П. Оценка частоты сопутствующей патологии у пациентов с ВИЧ-инфекцией в период сочетанной терапии. Инфекционные болезни. 2024;22(1):45-52.
3. Bezabhe W. M., et al. Adherence to antiretroviral therapy and its outcomes among healthcare users in low- and middle-income countries. Patient Preference and Adherence. 2024;18:145-158. (РҚТ режими бузилиши оқибатлари)
4. Boccara F., et al. HIV and Cardiovascular Disease: Pathogenesis, Prevalence, and Clinical Management. Journal of the American College of Cardiology. 2020;75(22):2856-2869.
5. Deeks S. G., Lewin S. R., Havlir D. V. The end of AIDS: HIV infection as a chronic disease. The Lancet. 2013;382(9903):1525-1533.
6. Guaraldi G., Palella F. J. Clinical management of the aging patient with HIV. The Lancet HIV. 2022;9(11):e792-e803.
7. Marzolini C., et al. Polypharmacy and drug-drug interactions in older people living with HIV. Current Opinion in HIV and AIDS. 2021;16(2):119-126.
8. Nachega J. B., et al. Adherence to antiretroviral therapy in HIV-positive adults: aging, comorbidities, and polypharmacy. Current Opinion in HIV and AIDS. 2023;18(2):89-97. (Қарилик ва полипрагмазиянинг хайрихоҳликка таъсири)
9. Rockstroh J. K., et al. Non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in HIV-monoinfected and HIV/HCV-coinfected patients. Journal of Hepatology. 2021;74(4):912-921.
10. Shubber Z., et al. Patient-reported barriers to adherence to antiretroviral therapy: A systematic review and meta-analysis. PLOS Medicine. 2023;20(3):e1004150. (Хайрихоҳлик тўсиқлари бўйича мета-таҳлил)
11. Smith J., et al. Comorbidities and aging in individuals with HIV on long-term ART: A multicenter cohort study. AIDS. 2023;37(5):745-754.
12. UNAIDS. Global HIV & AIDS statistics — Fact sheet. UNAIDS; 2024.
13. WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021.
